Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

Oluwadunni E. Emiloju, Jun Yin, Emily Koubek, Joel M. Reid, Mitesh J. Borad, Yanyan Lou, Mahesh Seetharam, Martin J. Edelman, Edward A. Sausville, Yixing Jiang, Ahmed O. Kaseb, James A. Posey, Sarah L. Davis, Gregory J. Gores, Lewis R. Roberts, Naoko Takebe, Gary K. Schwartz, Andrea E.Wahner Hendrickson, Scott H. Kaufmann, Alex A. AdjeiJoleen M. Hubbard, Brian A. Costello

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science